

PATENT ASSIGNMENT

Electronic Version v1.1
Stylesheet Version v1.1

SUBMISSION TYPE:	CORRECTIVE ASSIGNMENT										
NATURE OF CONVEYANCE:	Corrective Assignment to correct the name of the Assignee from "Pharmena Spolka Akcyjna (Pharmena S.A.)" to – Pharmena Spolka Acyjna (Pharmena S.A.) – previously recorded on Reel 024129 Frame 0708. Assignor(s) hereby confirms the Assignee's name is Pharmena Spolka Acyjna (Pharmena S.A.).										
CONVEYING PARTY DATA											
<table border="1"><thead><tr><th>Name</th><th>Execution Date</th></tr></thead><tbody><tr><td>Jerzy GEBICKI</td><td>03/08/2010</td></tr><tr><td>Stefan CHLOPICKI</td><td>02/25/2010</td></tr></tbody></table>		Name	Execution Date	Jerzy GEBICKI	03/08/2010	Stefan CHLOPICKI	02/25/2010				
Name	Execution Date										
Jerzy GEBICKI	03/08/2010										
Stefan CHLOPICKI	02/25/2010										
RECEIVING PARTY DATA											
<table border="1"><tr><td>Name:</td><td>Pharmena Spolka Acyjna (Pharmena S.A.)</td></tr><tr><td>Street Address:</td><td>ul. Dostawcza 12</td></tr><tr><td>City:</td><td>Lodz</td></tr><tr><td>State/Country:</td><td>POLAND</td></tr><tr><td>Postal Code:</td><td>93-231</td></tr></table>		Name:	Pharmena Spolka Acyjna (Pharmena S.A.)	Street Address:	ul. Dostawcza 12	City:	Lodz	State/Country:	POLAND	Postal Code:	93-231
Name:	Pharmena Spolka Acyjna (Pharmena S.A.)										
Street Address:	ul. Dostawcza 12										
City:	Lodz										
State/Country:	POLAND										
Postal Code:	93-231										
PROPERTY NUMBERS Total: 1											
<table border="1"><thead><tr><th>Property Type</th><th>Number</th></tr></thead><tbody><tr><td>Application Number:</td><td>12685377</td></tr></tbody></table>		Property Type	Number	Application Number:	12685377						
Property Type	Number										
Application Number:	12685377										
CORRESPONDENCE DATA											
Fax Number: (202)371-2540 <i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i> Phone: 2023712600 Email: mcimbala@skgf.com Correspondent Name: Sterne, Kessler, Goldstein & Fox P.L.L.C Address Line 1: 1100 New York Avenue, NW Address Line 4: Washington, DISTRICT OF COLUMBIA 20005											
ATTORNEY DOCKET NUMBER:	2782.0010002/MAC										
NAME OF SUBMITTER:	Michele A. Cimbala, Reg. No. 33,851										
Total Attachments: 6											

OP \$40.00 12685377

501151563

PATENT
REEL: 024251 FRAME: 0124

source=27820010002_corrective_assignment#page1.tif
source=27820010002_corrective_assignment#page2.tif
source=27820010002_corrective_assignment#page3.tif
source=27820010002_corrective_assignment#page4.tif
source=27820010002_corrective_assignment#page5.tif
source=27820010002_corrective_assignment#page6.tif

TO:MICHELE A. CIMBALA COMPANY:1100 NEW YORK AVENUE, NW

PATENT ASSIGNMENT

Electronic Version v1.1
Stylesheet Version v1.103/24/2010
501128228

SUBMISSION TYPE:	NEW ASSIGNMENT										
NATURE OF CONVEYANCE:	ASSIGNMENT										
CONVEYING PARTY DATA											
<table border="1"><thead><tr><th>Name</th><th>Execution Date</th></tr></thead><tbody><tr><td>Jerzy GEBICKI</td><td>03/08/2010</td></tr><tr><td>Stefan CHLOPICKI</td><td>02/25/2010</td></tr></tbody></table>		Name	Execution Date	Jerzy GEBICKI	03/08/2010	Stefan CHLOPICKI	02/25/2010				
Name	Execution Date										
Jerzy GEBICKI	03/08/2010										
Stefan CHLOPICKI	02/25/2010										
RECEIVING PARTY DATA											
<table border="1"><tr><td>Name:</td><td>Pharmena Spolka Akcyjna (Pharmena S.A.)</td></tr><tr><td>Street Address:</td><td>ul. Dostawcza 12</td></tr><tr><td>City:</td><td>Lodz</td></tr><tr><td>State/Country:</td><td>POLAND</td></tr><tr><td>Postal Code:</td><td>93-231</td></tr></table>		Name:	Pharmena Spolka Akcyjna (Pharmena S.A.)	Street Address:	ul. Dostawcza 12	City:	Lodz	State/Country:	POLAND	Postal Code:	93-231
Name:	Pharmena Spolka Akcyjna (Pharmena S.A.)										
Street Address:	ul. Dostawcza 12										
City:	Lodz										
State/Country:	POLAND										
Postal Code:	93-231										
PROPERTY NUMBERS Total: 1											
<table border="1"><thead><tr><th>Property Type</th><th>Number</th></tr></thead><tbody><tr><td>Application Number:</td><td>12685377</td></tr></tbody></table>		Property Type	Number	Application Number:	12685377						
Property Type	Number										
Application Number:	12685377										
CORRESPONDENCE DATA											
Fax Number: (202)371-2540 <i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>											
Phone: 2023712600											
Email: mcimbala@skgf.com											
Correspondent Name: Michele A. Cimbala											
Address Line 1: 1100 New York Avenue, NW											
Address Line 4: Washington, DISTRICT OF COLUMBIA 20005											
ATTORNEY DOCKET NUMBER:	2782.0010002										
NAME OF SUBMITTER:	Michele A. Cimbala, Reg. No. 33,851										
Total Attachments: 4 source=27820010002assignment#page1.tif source=27820010002assignment#page2.tif source=27820010002assignment#page3.tif											

OP \$40.00 12685377

TO:MICHELE A. CIMBALA COMPANY:1100 NEW YORK AVENUE, NW

source=27820010002assignment#page4.tif

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: **Jerzy GĖBICKI and Stefan CHŁOPICKI**, hereby sell and assign to **Pharmena Spółka Acyjna (Pharmena S.A.)**, a corporation formed under the laws of Poland, whose mailing address is ul. Dostawcza 12, 93-231 Lodz, Poland (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as **Use of Quaternary Pyridinium Salts as Vasoprotective Agents** for which application(s) for patent in the United States of America has a filing date or a 371(c) date of January 11, 2010 (also known as United States Application No. 12/685,377), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventors hereby represent that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the inventors.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: March 8, 2010

Signature of Inventor: _____

Jerzy GEBICKI

Date: _____

Signature of Inventor: _____

Stefan CHLOPICKI

1078381_1.DOC

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: **Jerzy GȨBICKI and Stefan CHŁOPICKI**, hereby sell and assign to **Pharmena Spółka Acyjna (Pharmena S.A.)**, a corporation formed under the laws of Poland, whose mailing address is ul. Dostawcza 12, 93-231 Lodz, Poland (hereafter referred to as the Assignee), his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as **Use of Quaternary Pyridinium Salts as Vasoprotective Agents** for which application(s) for patent in the United States of America has a filing date or a 371(c) date of January 11, 2010 (also known as United States Application No. 12/685,377), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

The undersigned inventors hereby represent that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventors hereby grant the patent practitioners associated with **CUSTOMER NUMBER 26111** the power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

The undersigned inventors hereby represent that he/she understands that the patent practitioners associated with **CUSTOMER NUMBER 26111** are the legal representatives of, and attorneys for, the assignee, and are NOT the legal representatives of, and attorneys for, the inventors.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his/her name.

Date: _____

Signature of Inventor: _____
Jerzy GĘBICKI

Date: 25.02.2010

Signature of Inventor: _____
Stefan CHŁOPICKI

1078381_1.DOC